Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semaglutide

Ozempic, Rybelsus, Wegovy

A long-acting GLP-1 receptor agonist used for type 2 diabetes and obesity management by enhancing insulin secretion and suppressing appetite.

Molecular Profile
Formula C187H291N45O59
Mol. Weight 4113.58 g/mol
Sequence Gly-Glu-Pro-Pro...
Clinical Data Trials
Scientific Data Studies
Route
Subcutaneous (SC)
0.25-2.4 mg weekly
SUB
Oral
3-14 mg daily
ORA

How It Works

How It Works: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1, regulating glucose homeostasis and energy intake.

  • Binds to GLP-1 receptors on beta cells to stimulate glucose-dependent insulin secretion.
  • Inhibits glucagon release from alpha cells in a glucose-dependent manner.
  • Delays gastric emptying to attenuate postprandial glucose excursions.
  • Acts centrally in the brain to increase satiety and reduce caloric intake.

Pairs Well With

TB
TB-500
Systemic repair
Cu
GHK-Cu
Skin & collagen
KP
KPV
Anti-inflammatory
Ip
Ipamorelin
GH secretagogue

Latest Clinical Trials

Not Yet Recruiting PHASE2, PHASE3 NCT05646199

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

University of Hull
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting NA NCT05040087

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Foundation for Atlanta Veterans Education and Research, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed PHASE4 NCT05813249

Semaglutide in Nonalcoholic Fatty Liver Disease

Zagazig University
INTERVENTIONAL
Updated Dec 15, 2025
View All Clinical Trials

Latest Studies

Utility 3
pubmed Dec 11, 2025

Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.

Ibrahim. Ramzi R; Han. William W; Wang. Winston W; Kau. Ethan E; Said. Nada N; F...

In a large real‑world study, people with obesity and a type of heart failure called HFpEF who took GLP‑1 drugs like semaglutide did better than those who had weight‑loss surgery. They had fewer heart‑failure flare‑ups, lived longer, and spent less time in the hospital, while losing about the same amount of weight. This suggests GLP‑1 drugs can be a powerful, non‑surgical option for managing weight and heart health in this high‑risk group.

Utility 4
pubmed Dec 11, 2025

Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.

Mondoh. Alvin A; Crotty. Michael M; le Roux. Carel W CW

The review compares two popular weight‑loss drugs—semaglutide (Ozempic) and tirzepatide (Mounjaro). It shows that both work well for obesity, but tirzepatide tends to cause bigger drops in weight while semaglutide is especially strong at protecting the heart. The paper pulls together results from big clinical trials to help people decide which drug might fit their goals.

Utility 2
pubmed Dec 10, 2025

Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Geary. Anne A

The article reviews metabolic‑associated fatty liver disease (MASLD), its link to insulin resistance and heart disease, and how primary‑care providers can spot it early using simple blood‑based scores and ultrasound‑based stiffness tests. It highlights that the drug resmetirom is now FDA‑approved for certain liver fibrosis cases, and notes that semaglutide is being studied as a possible future treatment for early‑stage disease, but no detailed results are given yet.

Browse All Studies